Determination of the efficacious and safe dose of ivabradine in paediatric patients with dilated cardiomyopathy and symptomatic chronic heart failure aged from 6 months to less than 18 years

Mise à jour : Il y a 4 ans
Référence : EUCTR2011-001292-39

Femme et Homme

  • | Pays :
  • -
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

To determine the optimal dose of ivabradine to reach the target heart rate reduction (HRR) of 20% without inducing a bradycardia (i.e. HR should be greater than a predefined HR threshold by age subset) and/or signs or symptoms related to bradycardia, ­To assess the pharmacokinetic (PK) parameters of ivabradine and its active metabolite S 18982 after repeated oral administrations, ­To assess the PKPD relationship of ivabradine and its active metabolite S 18982 using heart rate as evaluation criterion.


Critère d'inclusion

  • Paediatric dilated cardiomyopathy and symptomatic chronic heart failure